Journal of Cardiovascular Pharmacology, 1533-4023

Journal

More filtering options
  1. 2019
  2. Exploration of Physiological and Pathophysiological Implications of miRNA-143 and miRNA-145 in Cerebral Arteries

    Simon Topp Christensen, Sara Ellinor Johansson, Karin Warfvinge, Thomas Braun, Thomas Boettger, Lars Edvinsson & Kristian Agmund Haanes, 2019, In : Journal of Cardiovascular Pharmacology. 74, 5, p. 409-419 11 p.

    Research output: Contribution to journalArticle

  3. 2013
  4. Markers of inflammation, endothelial activation, and arterial stiffness in hypertensive heart disease and the effects of treatment: results from the SILVHIA study

    Andreas Jekell, Karin Malmqvist, N Håkan Wallén, David Mörtsell & Thomas Kahan, 2013 Dec, In : Journal of Cardiovascular Pharmacology. 62, 6, p. 559-66

    Research output: Contribution to journalArticle

  5. 2012
  6. Levosimendan attenuates hypoxia-induced pulmonary hypertension in a porcine model.

    Annaeva Wiklund, David Kylhammar & Göran Rådegran, 2012, In : Journal of Cardiovascular Pharmacology. 59, 5, p. 441-449

    Research output: Contribution to journalArticle

  7. 2010
  8. Comparison of the Vasoconstrictor Effects of the Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist Telcagepant (MK-0974) and Zolmitriptan in Human Isolated Coronary Arteries.

    Joseph J Lynch, Christopher P Regan, Lars Edvinsson, Richard J Hargreaves & Stefanie A Kane, 2010, In : Journal of Cardiovascular Pharmacology. 55, 5, p. 518-521

    Research output: Contribution to journalArticle

  9. 2006
  10. 2005
  11. Triptans Induce Vasoconstriction of Human Arteries and Veins from the Thoracic Wall.

    Angelica Wackenfors, Malin Jarvius, Richard Ingemansson, Lars Edvinsson & Malin Malmsjö, 2005, In : Journal of Cardiovascular Pharmacology. 45, 5, p. 476-484

    Research output: Contribution to journalArticle

  12. 2002
  13. P2 Receptor Expression Profiles in Human Vascular Smooth Muscle and Endothelial Cells.

    Lingwei Wang, Lena Karlsson, Sara Moses, Anna Hultgårdh-Nilsson, Maria Andersson, Catharina Cedercrantz-Borna, Tomas Gudbjartsson, Sverker Jern & David Erlinge, 2002, In : Journal of Cardiovascular Pharmacology. 40, 6, p. 841-853

    Research output: Contribution to journalArticle

  14. 1998
  15. Inhibition of angiotensin II-induced contraction by losartan in human coronary arteries

    Anton Holmgren, Emil Pantev, David Erlinge & Lars Edvinsson, 1998, In : Journal of Cardiovascular Pharmacology. 32, 4, p. 662-664

    Research output: Contribution to journalArticle

  16. 1996
  17. Contractile effects of neuropeptide Y in human subcutaneous resistance arteries are mediated by Y1 receptors

    Torun Nilsson, David Erlinge, Leonor Cantera & Lars Edvinsson, 1996, In : Journal of Cardiovascular Pharmacology. 28, 6, p. 764-768

    Research output: Contribution to journalArticle

  18. 1995
  19. Effects of the combined ETA and ETB receptor antagonist PD145065 on arteries, arterioles, and veins in the cat hindlimb

    Ulf Ekelund, Mikael Adner, Lars Edvinsson & Stefan Mellander, 1995, In : Journal of Cardiovascular Pharmacology. 26, Suppl. 3, p. 211-213

    Research output: Contribution to journalArticle

  20. Upregulation of a non-ETA receptor in human arteries in vitro

    Mikael Adner, David Erlinge, Lars Nilsson & Leif Edvinsson, 1995, In : Journal of Cardiovascular Pharmacology. 26, Suppl. 3, p. 314-316

    Research output: Contribution to journalArticle

  21. 1994
  22. Effects of carvedilol on the metabolic, hemodynamic, and electrocardiographic responses to increased plasma epinephrine in normal subjects

    Ole Hansen, B W Johansson, Peter Nilsson-Ehle, B Eklund, I Ohlsson, E Palenmark, Ann-Mari Pauler & K Svensson, 1994, In : Journal of Cardiovascular Pharmacology. 24, 6, p. 853-859

    Research output: Contribution to journalArticle

  23. 1991
  24. 1988
  25. 1987